KR880000463A - 사슬 결합법 - Google Patents
사슬 결합법 Download PDFInfo
- Publication number
- KR880000463A KR880000463A KR1019870006320A KR870006320A KR880000463A KR 880000463 A KR880000463 A KR 880000463A KR 1019870006320 A KR1019870006320 A KR 1019870006320A KR 870006320 A KR870006320 A KR 870006320A KR 880000463 A KR880000463 A KR 880000463A
- Authority
- KR
- South Korea
- Prior art keywords
- human
- chain
- reduced form
- analog
- relaxine
- Prior art date
Links
- 101150118523 LYS4 gene Proteins 0.000 claims description 7
- 238000000034 method Methods 0.000 claims 11
- BJRCFZKVYNDCJE-WBSNEMHCSA-N 99489-95-9 Chemical compound C([C@@H]1NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)NCC(=O)N2)[C@@H](C)CC)=O)CSSC[C@@H](C(NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC1=O)C(O)=O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O)[C@@H](C)CC)[C@@H](C)CC)C(C)C)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)CCCCN)C(C)C)[C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCNC(N)=N)C(C)C)C1=CC=C(O)C=C1 BJRCFZKVYNDCJE-WBSNEMHCSA-N 0.000 claims 4
- 150000001413 amino acids Chemical group 0.000 claims 4
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims 3
- 101500024628 Homo sapiens Relaxin B chain Proteins 0.000 claims 3
- 101500024640 Homo sapiens Relaxin B chain Proteins 0.000 claims 3
- 101500024627 Homo sapiens Relaxin A chain Proteins 0.000 claims 2
- 101500024645 Homo sapiens Relaxin A chain Proteins 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000001737 promoting effect Effects 0.000 claims 2
- KREXTMSNGTWUJT-YWPYICTPSA-N 2-[[2-[[(2r,3s,5r)-3-[[2-(carboxymethylamino)-2-oxoethyl]carbamoyloxy]-5-[2-(2-methylpropanoylamino)-6-oxo-3h-purin-9-yl]oxolan-2-yl]methoxycarbonylamino]acetyl]amino]acetic acid Chemical compound C1=NC=2C(=O)NC(NC(=O)C(C)C)=NC=2N1[C@H]1C[C@H](OC(=O)NCC(=O)NCC(O)=O)[C@@H](COC(=O)NCC(=O)NCC(O)=O)O1 KREXTMSNGTWUJT-YWPYICTPSA-N 0.000 claims 1
- 101100455762 Aspergillus niger (strain CBS 513.88 / FGSC A1513) lysA gene Proteins 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 101100289883 Schizosaccharomyces pombe (strain 972 / ATCC 24843) lys2 gene Proteins 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 230000035606 childbirth Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 108010004459 relacin Proteins 0.000 claims 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 238000009739 binding Methods 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 241000212384 Bifora Species 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- VFNGKCDDZUSWLR-UHFFFAOYSA-N disulfuric acid Chemical class OS(=O)(=O)OS(O)(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/64—Relaxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/26—Containing cys-cys disulfide bridge between nonadjacent cysteine residues
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
내용없음
Description
제1도는 인체 렐락신 H1 및 H2, 인체 인슐린 및 돼지(P) 및 쥐(R)렐락신 사이에 동일성이 없음을 나타낸 것임. 번호는 H2 렐락신에 대하여 상대적인 것이고 렐락신의 이황산염은 A10-A15, A11-B11 및 A24-B23임.
제2(a)도는 시험관 내 사슬 결합반응에 있어서 H2(B33 A24)BLys4BAla25프로필의 HPLC시간 경로를 , 제2(b)도는 H2(B33 A24)프로필의 HPLC경로를 나타낸 것임. 여기서는 인체 렐락신 유사체 또는 인체 렐락신 및 잠재적으로 중요한 A사슬의 분자내 산화 중간체의 형성을 나타내는 결합 반응의 시간 경로를 나타내었음. 또한 유전자 2A 및 B사슬 펩티드의 H2 인체 렐락신 유사체 및 H2 인체 렐락식 에로의 전화을 나타내었음 Synchrak RP-C4(4.6×2.5mm;300A°)을 사용하여 크로마토그래피하였고, 1m/min의 속도로 용출시킨 0.05% TFA, H2O 완충액 중의 아세토니트릴 선형 구배는 500분 동안 15-60%이었음.
제3도는 인체 유전자 2렐락신 H2(B2-33 A24)BLysBAla25천연 인체 렐락신 결합 사슬의 생체 활성(MPS)을 나타낸 것임.
제4도는 다양한 복용량의 인체 렐락신 유사체 H2(B2-33 A24)BLys4BAla25및 H2(B33 A24)BLys4BAla25가 투여된 영장류의 변형된 비숍 스코어를 나타낸 것임.
Claims (16)
- A사슬의 환원된 형태 및 B 사슬의 환원된 형태를 pH 약 7.0 내지 12의 배지 수용액 중에서 인체 렐락신 또는 인체 렐락신 유사체가 형성되는 렐락신 B사슬을 약간 변성시키는 조건하에서 혼합하는 것으로 되는 인체 렐락신 A사슬 또는 그의 유사체와 인체 렐락신 B사슬 또는 그의 유사체를 결합시켜 인체 렐락신 또는 인체 렐락신 유사체를 제조하는 방법.
- 제1항에 있어서, 인체 렐락신 A사슬의 환원된 형태 및 인체 렐락신 B사슬의 환원된 형태 각각이 천연 인체 렐락신(H2)로 표시되는 아미노산 서열을 갖는 것인 방법.
- 제1항에 있어서, 인체 렐락신 A사슬의 환원된 형태 및 인체 렐락신 B사슬의 환원된 형태 각각이 천연 인체 렐락신(H1)으로 표시되는 아미노산 서열을 갖는 것인 방법.
- 제1항에 있어서, 인체 렐락신 A사슬의 환원된 형태가 상기 A사슬의 유사체인 방법.
- 제1항에 있어서, 인체 렐락신 B사슬의 환원된 형태가 상기 B사슬의 유사체인 방법.
- 제1항에 있어서, 인체 렐락신 B사슬의 환원된 형태가 적어도 25개, 최대로 33개의 아미노산을 가지며 사슬중에서 적어도 하나의 메티오닌으로 치환된 방법.
- 제1항에 있어서, 인체 렐락신 B사슬의 환원된 형태가 사슬중 제4지점에 리신을 가지며 제25지점에 알라닌을 갖는 32개의 아미노산으로 줄어든 것인 방법.
- 제1항에 있어서, 약 15℃-30℃의 온도에서 혼합시키는 방법.
- 제1항에 있어서, 실온에서 혼합시키는 방법.
- 제1항에 있어서, 인체 렐락신 A사슬의 환원된 형태가 사슬의 제1지점에서 Pyro-Glu를 갖는 것인 방법.
- 인체 렐락신 유사체 H2(B33 A24)BLys4BAla25
- 인체 렐락신 유사체 H2(B2-33 A24)Blys4BAla25
- 인체 렐락신 유사체 H2(B2-33 A24)BLys4BAla25APyro-Glu′
- 인체 렐락신 유사체 H2(B33 A24)BLys4BAla25APyro-Glu′
- 유일한 활성제인 인체 렐락신 및 제약상 허용되는 담체로 되는 제약 조성물을 투여하여 분만을 촉진시키는 방법.
- 유일한 활성제인 인체 렐락신 유사체 및 제약상 허용되는 담체로 되는 제약 조성물을 투여하여 분만을 촉진시키는 방법.※참고사항:최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/877,819 US4835251A (en) | 1986-06-23 | 1986-06-23 | Method of chain combination |
| US877819 | 1986-06-23 | ||
| US06/877,819 | 1986-06-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR880000463A true KR880000463A (ko) | 1988-03-26 |
| KR960007604B1 KR960007604B1 (ko) | 1996-06-07 |
Family
ID=25370787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019870006320A KR960007604B1 (ko) | 1986-06-23 | 1987-06-22 | 인체 렐락신 또는 그 유사체를 제조하는 방법 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US4835251A (ko) |
| EP (1) | EP0251615B1 (ko) |
| JP (1) | JP2529693B2 (ko) |
| KR (1) | KR960007604B1 (ko) |
| CN (1) | CN1029784C (ko) |
| AU (1) | AU617291B2 (ko) |
| CA (1) | CA1336223C (ko) |
| DE (1) | DE3783273T2 (ko) |
| DK (1) | DK173649B1 (ko) |
| HU (1) | HU205948B (ko) |
| IE (1) | IE59683B1 (ko) |
| IL (1) | IL82921A (ko) |
| PH (1) | PH23407A (ko) |
| PT (1) | PT85134B (ko) |
| ZA (1) | ZA874482B (ko) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5191063A (en) * | 1989-05-02 | 1993-03-02 | University Of Medicine And Dentistry Of New Jersey | Production of biologically active polypeptides by treatment with an exogenous peptide sequence |
| CA2051375C (en) * | 1989-05-04 | 2000-09-12 | Dennis J. Henner | Process and compositions for the isolation of human relaxin |
| US5478807A (en) * | 1991-08-19 | 1995-12-26 | Genentech, Inc. | Use of relaxin in the treatment of bradycardia |
| US5166191A (en) * | 1991-08-19 | 1992-11-24 | Genentech, Inc. | Use of relaxin in cardiovascular therapy |
| US5911997A (en) * | 1995-06-07 | 1999-06-15 | Connetics Corporation | Relaxin-like factor and methods and uses thereof |
| US5612051A (en) * | 1995-11-17 | 1997-03-18 | Yue; Samuel K. | Method of treating involuntary muscle dysfunction with relaxin hormone |
| US6709659B1 (en) * | 1996-08-02 | 2004-03-23 | Zymogenetics, Inc. | Antibodies that bind testis-specific insulin homolog polypeptides |
| US5994148A (en) * | 1997-06-23 | 1999-11-30 | The Regents Of University Of California | Method of predicting and enhancing success of IVF/ET pregnancy |
| US6251863B1 (en) | 1998-09-08 | 2001-06-26 | Samuel K. Yue | Method of preventing and treating symptoms of aging and neurodegenerative dysfunctions with relaxin |
| US20050032683A1 (en) * | 2000-10-04 | 2005-02-10 | Amento Edward P. | Methods of modulating apoptosis by administration of relaxin agonists or antagonists |
| US20050186526A1 (en) * | 2002-11-01 | 2005-08-25 | Bas Medical, Inc. | Methods and systems for enabling and stabilizing tooth movement |
| AU2003903124A0 (en) * | 2003-06-20 | 2003-07-10 | Mark Del Borgo | Analogues of heteromeric proteins |
| WO2005115435A2 (en) | 2004-04-30 | 2005-12-08 | Bas Medical, Inc. | Methods and compositions for control of fetal growth via modulation of relaxin |
| US20060052304A1 (en) * | 2004-09-02 | 2006-03-09 | Bas Medical, Inc. | Method for remodeling bone and related sutures |
| WO2007115414A1 (en) * | 2006-04-11 | 2007-10-18 | University Of Guelph | Modified h2 relaxin for tumor suppression |
| GR1006759B (el) * | 2008-12-22 | 2010-04-20 | Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras) | Εξελιγμενη χημικη μεθοδος συνθεσης της ανθρωπινης ρηλαξινης |
| GR1006941B (el) * | 2009-06-01 | 2010-08-27 | Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), | Πεπτιδικη συνθεση (peptide synthesis) |
| GR1007010B (el) | 2009-10-08 | 2010-10-07 | Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), | Ινσουλινοειδη πεπτιδια |
| MY162837A (en) | 2010-08-17 | 2017-07-31 | Ambrx Inc | Modified relaxin polypeptides and their uses |
| US20160152679A1 (en) * | 2012-05-24 | 2016-06-02 | Angion Biomedica Corp. | Relaxin-like compounds and uses thereof |
| US9381231B2 (en) | 2012-10-09 | 2016-07-05 | University Of Florida Research Foundation, Inc. | Use of relaxin to restore maternal physiology in pregnancies conceived by assisted reproductive technologies |
| JP6289937B2 (ja) * | 2014-02-27 | 2018-03-07 | 学校法人東海大学 | リラキシンの製造方法 |
| EP2946788A1 (en) | 2014-05-23 | 2015-11-25 | Immundiagnostik AG | Method and composition for treating heart failure with preserved ejection fraction |
| JP2018532810A (ja) | 2015-11-07 | 2018-11-08 | マルチビア インコーポレイテッド | がんの処置のための腫瘍抑制因子遺伝子治療および免疫チェックポイント治療を含む組成物 |
| CN110381997A (zh) | 2016-12-12 | 2019-10-25 | 茂体外尔公司 | 用于治疗和预防癌症和感染性疾病的包含病毒基因治疗和免疫检查点抑制剂的方法和组合物 |
| CN112020510A (zh) | 2018-03-19 | 2020-12-01 | 茂体外尔公司 | 包含用于治疗癌症的肿瘤抑制基因疗法和cd122/cd132激动剂的方法及组合物 |
| KR20220031044A (ko) | 2019-07-31 | 2022-03-11 | 일라이 릴리 앤드 캄파니 | 릴랙신 유사체 및 이를 사용하는 방법 |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| WO2021226439A2 (en) * | 2020-05-08 | 2021-11-11 | President And Fellows Of Harvard College | Engineered relaxins and methods of use thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL128599B1 (en) * | 1980-03-27 | 1984-02-29 | Lilly Co Eli | Insulin obtaining method |
| US4421685A (en) * | 1980-03-27 | 1983-12-20 | Eli Lilly And Company | Process for producing an insulin |
| US4656249A (en) * | 1982-06-10 | 1987-04-07 | Howard Florey Institute Of Experimental Physiology And Medicine | Peptides with relaxin activity |
| ATE78042T1 (de) * | 1982-08-12 | 1992-07-15 | Florey Howard Inst | Analoge des humanen relaxins. |
| AU562962B2 (en) * | 1982-08-12 | 1987-06-25 | Howard Florey Institute Of Experimental Physiology And Medicine | Molecular cloning and characterisation of the gene sequence coding for human relaxin |
| NZ206534A (en) * | 1982-12-13 | 1988-05-30 | Florey Howard Inst | Molecular cloning and characterisation of gene sequence coding for human relaxin |
| AU562713B2 (en) * | 1982-12-13 | 1987-06-18 | Howard Florey Institute Of Experimental Physiology And Medicine | Cloning for human relaxin |
-
1986
- 1986-06-23 US US06/877,819 patent/US4835251A/en not_active Expired - Lifetime
-
1987
- 1987-06-19 IL IL82921A patent/IL82921A/xx not_active IP Right Cessation
- 1987-06-19 DK DK198703130A patent/DK173649B1/da not_active IP Right Cessation
- 1987-06-19 HU HU872804A patent/HU205948B/hu not_active IP Right Cessation
- 1987-06-19 PH PH35432A patent/PH23407A/en unknown
- 1987-06-22 EP EP87305508A patent/EP0251615B1/en not_active Expired - Lifetime
- 1987-06-22 IE IE165587A patent/IE59683B1/en not_active IP Right Cessation
- 1987-06-22 PT PT85134A patent/PT85134B/pt not_active IP Right Cessation
- 1987-06-22 DE DE8787305508T patent/DE3783273T2/de not_active Expired - Lifetime
- 1987-06-22 KR KR1019870006320A patent/KR960007604B1/ko not_active IP Right Cessation
- 1987-06-22 ZA ZA874482A patent/ZA874482B/xx unknown
- 1987-06-23 JP JP62156391A patent/JP2529693B2/ja not_active Expired - Lifetime
- 1987-06-23 CA CA000540413A patent/CA1336223C/en not_active Expired - Lifetime
- 1987-06-23 AU AU74620/87A patent/AU617291B2/en not_active Expired
- 1987-06-23 CN CN87104447A patent/CN1029784C/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US4835251A (en) | 1989-05-30 |
| HUT44045A (en) | 1988-01-28 |
| IL82921A (en) | 1992-01-15 |
| DK313087D0 (da) | 1987-06-19 |
| CN87104447A (zh) | 1988-02-10 |
| IE871655L (en) | 1987-12-23 |
| ZA874482B (en) | 1989-02-22 |
| AU617291B2 (en) | 1991-11-28 |
| HU205948B (en) | 1992-07-28 |
| DE3783273T2 (de) | 1993-05-27 |
| CN1029784C (zh) | 1995-09-20 |
| PT85134A (en) | 1987-07-01 |
| JPS6366198A (ja) | 1988-03-24 |
| DK313087A (da) | 1987-12-24 |
| EP0251615B1 (en) | 1992-12-30 |
| PT85134B (pt) | 1990-03-30 |
| DK173649B1 (da) | 2001-05-21 |
| PH23407A (en) | 1989-07-26 |
| EP0251615A2 (en) | 1988-01-07 |
| KR960007604B1 (ko) | 1996-06-07 |
| JP2529693B2 (ja) | 1996-08-28 |
| AU7462087A (en) | 1987-12-24 |
| EP0251615A3 (en) | 1989-12-13 |
| DE3783273D1 (de) | 1993-02-11 |
| CA1336223C (en) | 1995-07-04 |
| IE59683B1 (en) | 1994-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR880000463A (ko) | 사슬 결합법 | |
| US5164370A (en) | Peptide analogues of insulin-like growth factor 1 (igf-1) or factor 2 (igf-2) | |
| CA1341207C (en) | Analogues of insulin-like growth factor-1 | |
| US4871835A (en) | Analogs of hGH having antagonistic activity, and uses thereof | |
| FI79786C (fi) | Foerfarande foer framstaellning ett farmaceutiskt medel foer behandling av diabetes. | |
| US5470828A (en) | Peptide analogs of insulin-like growth factor II | |
| JPH01156998A (ja) | 血清担体タンパク質との結合力が減少しているヒトインスリン様成長因子類以体及び酵母におけるそれらの産生 | |
| KR970706842A (ko) | 아실화된 인슐린 동족체(Acylated Insulin Analogs) | |
| CA2149048A1 (en) | Modified insulin-like growth factors | |
| DE19908041A1 (de) | Kovalent verbrückte Insulindimere | |
| JPH10500693A (ja) | 改変型インスリン様増殖因子 | |
| US9963484B2 (en) | Polynucleotide encoding a fusion protein for improving skin conditions | |
| US5158935A (en) | Human epidermal growth factor having substitution at position 11 | |
| JPS6094998A (ja) | インシュリン誘導体の製法 | |
| JPH0273100A (ja) | 医薬用化合物 | |
| CA2311648A1 (en) | Ifnar2/ifn complex | |
| JPH08301899A (ja) | Ｉｇｆ−１スーパーアゴニスト | |
| EP0373540A2 (en) | Method for purifying fibroblast growth factor protein | |
| AU2005335186A1 (en) | Human growth hormone conjugated with biocompatible polymer | |
| US20060134736A1 (en) | Human growth hormone conjugated with biocompatible polymer | |
| JPH06220090A (ja) | ポリペプチド | |
| RU2119800C1 (ru) | Аналог пептида фактора гормона роста (фгр), способ стимулирования секреции гормона роста и композиция для стимулирования секреции | |
| KR890002395A (ko) | 인터루킨-2 활성을 갖는 폴리펩타이드 | |
| AU612776C (en) | Peptide analogues of insulin-like growth factor 1 (IGF-1) or factor 2 (IGF-2) | |
| HU201566B (en) | Process for producing new analoguse of activatin factor of human growth hormon and pharmaceutical and veterinair compositions containing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E902 | Notification of reason for refusal | ||
| G160 | Decision to publish patent application | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20030522 Year of fee payment: 8 |
|
| LAPS | Lapse due to unpaid annual fee |